Diabetes, Metabolic Syndrome, Obesity
Conditions
Keywords
Metabolic syndrome, Obesity, Diabetes
Brief summary
No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight.
Detailed description
we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.
Interventions
DRUGOlanzapine
Olanzapine in dose range of 10-20mg
DRUGRisperidone
Risperidone 1-6mg
DRUGHaloperidol
Haloperidol 10-20mg
Sponsors
Central Institute of Psychiatry, Ranchi, India
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18-40 years * Diagnosis of schizophrenia * Drug naive on admission
Exclusion criteria
* Other psychiatric co-morbidity * History of severe physical illness * Alcohol and substance abuse or dependence * History of pre-existing diabetes or hypertension * Family history of hypertension or diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study of metabolic profile | 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Study of obesity and diabetes | 6 weeks |
Countries
India
Outcome results
None listed